Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-02-01
2005-02-01
Lu, Frank W (Department: 1634)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C435S069100, C435S071100
Reexamination Certificate
active
06849716
ABSTRACT:
The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.
REFERENCES:
patent: 6390821 (2002-05-01), Shokat
patent: WO 9302209 (1993-02-01), None
patent: WO 9835048 (1998-08-01), None
Shah et al., Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc. Natl. Acad. Sci . U S A, 94, 3565-70, Apr. 1997.*
Singh et al., “Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases,”J. Med. Chem.40, 1130-1135 (1997).
Wilson et al., “The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP Kinase,”Chem.&Biol.4, 423-431 (1997).
Gum et al., “Acquisition of Sensitivity of Stress-Activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino acids within the ATP Binding Pocket,”J. Biol. Chem.273, 15605-15610 (1998).
Goldsmith et al., “Protein Kinases,”Curr. Opin. Struct. Biol.4, 833-840 (1994).
Johnson et al., “Active and Inactive Protein Kinases: Structural Basis for Regulation,”Cell85, 149-158 (1996).
Taylor et al., “Three Protein Kinase Structures Define a Common Motif,”Structure2, 345-355 (1994).
Fox Ted
Germann Ursula A.
Su Michael Shin-San
Wilson Keith Philip
Fish & Neave LLP
Haley Jr. James F.
Lu Frank W
Vertex Pharmaceuticals Incorporated
LandOfFree
Methods for designing inhibitors of serine/threonine kinases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for designing inhibitors of serine/threonine kinases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for designing inhibitors of serine/threonine kinases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463635